Www.OncologyEducation.ca Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

James R. Rigas Comprehensive Thoracic Oncology Program

C.P. Belani 1, T. Brodowicz 2, P. Peterson 3, W. John 3, G. Scagliotti 4 1 Penn State Cancer Institute, Hershey, PA USA; 2 Medical University, Vienna,

Non-small Cell Lung Cancer

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Questions and answers about PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC.

ECCO ESMO 2011 GI Cancer Updates “ VELOUR” Study Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Antiangiogenic Agents in Advanced NSCLC Jared Weiss, MD Assistant Professor of Medicine Division of Hematology and Oncology University of North Carolina.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

A single-arm phase II trial in p treated with C, D and B (15 mg/kg) every 3 weeks followed by B showed a promising efficacy, in terms of progression free.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.

Bevacizumab Update.

A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.

Bevacizumab: Antiangiogenic therapy for breast cancer: where do we stand? Fortunato Ciardiello Division of Medical Oncology, Department of Clinical and.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Lung cancer perspectives. Targeted therapy : one for all or a few for one ? Miklos Pless, Winterthur

FIRST-LINE THERAPY FOR ADVANCED NSCLC Rogerio C. Lilenbaum, MD Clinical Associate Professor of Medicine University of Miami School of Medicine Director,

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Cytotoxic Chemotherapy Produces Limited Benefit in Stage IV NSCLC All recent randomized chemotherapy studies have similar results Median survival: 8 mo.

O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.

Best of ASCO – Colorectal & Pancreatic Cancers Best of ASCO Colorectal & Pancreatic Cancers Ali Shamseddine, MD Professor of Medicine Head of Hematology/Oncology.

Pritchard KI et al. Proc SABCS 2010;Abstract P

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,

Vecchi e nuovi antiangiogenetici

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

until tumour progression until tumour progression

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.

Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by CapeOX plus BEV or single agent (s/a) BEV.

A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.

Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

ESMO 2016 Durvalumab Data Study / Abstract Ph Indication Line N Arms

ECCO ESMO 2011 GI Cancer Updates “VELOUR” Study

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

A cura di Filippo de Marinis

Azienda Ospedaliero Universitaria Policlinico Modena

Rosell R et al. Proc ASCO 2011;Abstract 7503.

SQUIRE: Improved Survival With Necitumumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin as First-line Treatment in Patients With Squamous NSCLC Slideset.

Intervista a Lucio Crinò

Bevacizumab in platinum-sensitive ovarian cancer: OCEANS.

Domenica 03 giugno Highlight a cura di Filippo de Marinis

1Sunnybrook Health Sciences Centre, University of Toronto, Canada

Presentation transcript:

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann Oncol 19:LBA1, 2008 Reviewed By: Dr. Ron Burkes Date posted: December 2008

BO (AVAIL): A Phase III Randomised Study of First-line Bevacizumab Combined with Cisplatin/Gemcitabine (CG) in Patients (PTS) with Advanced or Recurrent Non-Squamous, Non-small Cell Lung Cancer (NSCLC) Authors: Manegold et al

RANDOMISERANDOMISE *Stratification factors: disease stage, ECOG PS, region, gender PD Avastin Placebo CG Avastin 15mg/kg + CG Avastin 7.5mg/kg + CG Placebo 15 + CG Previously untreated, stage IIIb, IV or recurrent non- squamous NSCLC* R A N D O MI S E Primary endpoint: progression-free survival Secondary endpoints: overall survival, time to treatment failure, response rate Excluded patients with tumours invading or abutting major blood vessels Manegold, et al. ASCO 2007

PS 0,1 No uncontrolled hypertension No squamous pathology No CNS mets No previous thromboembolic disease No NSAIDs No anticoagulants No central tumors near or abutting major blood vessels No hemoptysis > gr 2 Highly Selected Patients

GC 347 GC + 7.5mg 345 GC + 15mg 351 RR20%34%30% MDR PFS (mo) OS (mo) (HR=.91)13.4 (HR=1.03) 2 nd -line Rx65%61% - TKI41%48%42% - CT73%65%69% Gemcitabine + Cisplatin +/- Bevacizumab as 1 st -line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann Oncol 19:LBA1, 2008

AVAIL: Cis/Gem +/- Avastin ESMO update: 7.5mg15mgplacebo median survival 13.4m13.6m13.1m PROGRESSION FREE SURVIVAL

Phase III trial of Avastin plus GC in NSCLC (AVAiL): Safety summary Event Placebo + CG (n=327) (%) Avastin 7.5mg/kg + CG (n=330) (%) Avastin 15mg/kg + CG (n=329) (%) Any grade 3–5 adverse event Serious adverse event Adverse events leading to death445 Manegold, et al. ASCO 2007

Phase III trial of Avastin plus GC in NSCLC (AVAiL): Severe adverse events of special interest *Includes arterial thromboembolic events Manegold, et al. ASCO 2007 Grade ≥3 event Placebo + CG (n=327) (%) Avastin 7.5mg/kg + CG (n=330) (%) Avastin 15mg/kg + CG (n=329) (%) Bleeding244 Hypertension269 Proteinuria– 0.31 GI perforation 0.6– 0.3 Ischaemic events*523 Venous thromboembolic events 677

Pulmonary Haemorrhage Events Of note: 38% of patients in AVAiL had central lesions 4/10 patients with severe pulmonary haemorrhage had central lesions 9% of patients in AVAiL had therapeutic anticoagulation –but none of them had a severe pulmonary haemorrhage Event, n (%) Placebo + CG (n=327) Avastin 7.5mg/kg + CG (n=330) Avastin 15mg/kg + CG (n=329) Pulmonary haemorrhage (all grades)17 (4.9)23 (7.0)32 (9.7) Pulmonary haemorrhage (grade  3) 2 (0.6) 5 (1.5) 3 (0.9) Fatal pulmonary haemorrhage 1 (0.3) 4 (1.2) 3 (0.9) Manegold, et al. ASCO 2007

ECOG 4599 vs AVAiL E4599 (15) 424 AVAiL (7.5) 345 A-GC 347 E-TCb 431 RR35%34%20%15% PFS MST yr S51.9%--43.7%

Study Commentary  Does this trial confirm ECOG 4599?  there is a very modest improvement in PFS BUT no survival benefit!!!  If one uses Taxol/Carboplatin then Bevacizumab appears to be necessary; however with a Cisplatin-based (GC) doublet the incremental benefit of bevacizumab is modest  Should we be using Bevacizumab as 1 st line Rx with chemotherapy for selected pts with advanced NSCLC?  If so with which regimen?  And if so what dose – 7.5 vs 15?